Author:
Li Yuchang,Chen Liting,Sottas Chantal,Raul Mahima Chandrakant,Patel Nrupa Dinesh,Bijja Janaki Ramulu,Ahmed S. Kaleem,Kapelanski-Lamoureux Audrey,Lazaris Anthoula,Metrakos Peter,Zambidis Alexander,Chopra Shefali,Li Meng,Sugahara Go,Saito Takeshi,Papadopoulos Vassilios
Funder
USC Alfred E Mann School of Pharmacy and Pharmaceutical Sciences
University of South China
NIH
Reference50 articles.
1. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates;Younossi;Clin Gastroenterol Hepatol,2019
2. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation;Ibrahim;Gut,2018
3. A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis;Harrison;N Engl J Med,2024
4. Mechanisms of NAFLD development and therapeutic strategies;Friedman;Nat Med,2018
5. New targets for NAFLD;Parlati;JHEP Rep,2021